Shots: The P-III OASIS-2 study involves assessing mirikizumab vs PBO & Cosentyx (secukinumab) in 1,465 patients with mod. to sev. PsO. The patients were randomized in a (4:4:4:1) ratio to […]readmore
Tags : OASIS-2
Shots: The P-III OASIS-2 study involves assessing of Nuzyra (qd, PO) vs Linezolid (PO, bid) in 735 patients with acute bacterial skin and skin structure infections (ABSSSI) The P-III OASIS […]readmore